Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults
Clinical trial NCT03220724 · COMPLETED
Trial details
- NCT number
- NCT03220724
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-22
- Primary completion
- 2023-03-21
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.